The modest efficacy and toxic effects of Bayer AG/Onyx Pharmaceuticals Inc.’s Stivarga (regorafenib) suggest the drug is unlikely to be cost-effective in advanced colon cancer, according to an editorial in the Lancet, in what is becoming a familiar refrain in the crowded, expensive treatment space.
The Nov. 22 editorial, written by U.K. oncologists, comes as the drug is under review in Europe for metastatic colorectal cancer, following a filing in May 2012. It accompanied publication...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?